Manganese, Possible Factor of Higher Mortality in Women With Encephalopathy
Trial Snapshot
- Phase
- Not Applicable
- Status
- Terminated
- Sponsor
- Enrollment
- 9
- Locations
- 1
- Primary Endpoint
- Clinical Evolution
Study Overview
Brief Summary
Objective:
Report manganese serum levels and mortality in encephalopathic patients.
Patients and participants:
Consecutive patients aged > 18 years, with hepatic encephalopathy and informed consent signed by their families.
Interventions:
Patients' clinical characteristics as well as biochemical tests of renal function, hemoglobin, glucose and albumin levels were obtained as well as a blood sample to analyze manganese levels with a graphite furnace atomic absorption spectrometer.
Hypothesis:
There is a difference in the manganese levels between male and female patients.
Study Design
- Study Type
- Observational
- Observational Model
- Case Only
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Consecutive patients aged > 18 years
- •With hepatic encephalopathy
- •Informed consent signed by their families
Exclusion Criteria
- •Portal bypass surgery
- •Cancer of any localization
- •Known malignancy and other severe diseases which shorten life expectancy < 6 months
- •Psychiatric illness
Outcomes
Primary Outcomes
Clinical Evolution
Time Frame: six months
Number of participants who died versus those who remained alive after 6 months of follow up since the first entrance at the Emergency Room
Secondary Outcomes
- Manganese Levels(Up to six months we followed the recruited patients to determine who were still alive)
